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LETTERS TO THE EDITORTHE DOG DIDN’T BARK
To the Editor:
The interesting article, ‘‘Outcome
and prognostic factors of pleural me-
sothelioma after surgical diagnosis
and/or pleurodesis’’1 recently pub-
lished in the Journal again illustrates
the universally lethal course of this
disease.
During the last 60 years, hundreds
of thousands of young patients world-
wide have undergone prophylactic
pleurodesis, typically for recurrent
spontaneous pneumothorax. These
patients have then risked the
‘‘normal’’ exposure to asbestos fibers
suffered by the general population.
Surprisingly, Middleton and col-
leagues2 state, ‘‘No documented cases
of pleural malignancy after instillation
of talc exist.’’
This seems extraordinary.
Although it seems counterintuitive,
whatever the mechanism, the signifi-
cance of this cannot be overlooked
and raises an important question.
Should a young individual with
evidence of asbestos-related pleural
disease also be free to consider pleu-
rodesis to prevent subsequent
development of mesothelioma?
Vincent Acton, FRANZCR
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We thank Dr Acton for his interest
in our work. Although some long-
term survivors exist, prognosis of non-
surgically treated malignant pleural
mesothelioma remains poor. This rai-
ses the question of identification of
subset of patients more likely to
benefit from an aggressive approach,
including extensive surgery. On the
other hand, with respect to his provoc-
ative thoughts about the possible effect
of talc in preventing mesothelioma,
some consideration is in order.
Talc has been used effectively as a
pleurodesis agent for several decades.
After some early concerns about
possible occurrence of malignancy,
no cases have been reported of lung
cancer or mesothelioma. Talc used
for pleural symphysis is asbestos free
and consists of large particles, to pre-
vent risks of embolization, pneu-
monia, or adult respiratory distress
syndrome. Indication for talc pleurod-
esis are mainly malignant effusion
and, to a lesser extent, pneumothorax.
We know of no precise estimate
regarding the number of patients
with long life expectancy (those with
pneumothorax) treated by talc pleu-
rodesis worldwide in the last decades,
although we are not fully convinced
by Dr Acton’s estimate of hundreds
of thousands. If his estimate is
accurate, the hypothesis of possible
protective effect of talc against meso-
thelioma would certainly be real,
considering the annual incidence of
mesothelioma (approximately 1.5/
100,000). Even if the estimate is
10-fold superior to the real number,
however, the lack of documentation
of cases of mesothelioma in patients
treated by talc pleurodesis still sug-
gests some considerations.ardiovascular Surgery c October 2013Talc is the most effective scle-
rosing agent, and the most widely
used in malignant pleural effusion.
The mechanisms of talc-induced
pleurodesis are complex and not
fully understood: diffuse inflamma-
tion, pleural coagulation-fibrinolysis
imbalance favoring the formation of
adhesions, recruitment and prolifera-
tion of fibroblasts, and collagen pro-
duction occur after instillation of
sclerosing agents.1 Normal pleural
mesothelial cells play a major role,
releasing several mediators, including
interleukin-8, transforming growth
factor-b and basic fibroblast growth
factor, and it has been pointed out
that relative preservation of the
pleural cavity (without massive tu-
moral infiltration) is a major predic-
tor of the success of pleurodesis.1
Nevertheless, it has been suggested
that clinical improvement of patients
with malignant pleural effusion after
talc pleurodesis is not related only to
the control of effusion. It has been
shown that pleural fluid of patients
receiving talc pleurodesis has
increased levels of endostatin
relative to control samples.2 Normal
pleural mesothelial cells would be
the origin of this increase, with a
resultant shift in the balance to local
angiostasis rather than angiogenesis.2
Furthermore, in vitro experiments
have suggested that, at a therapeuti-
cally achievable concentration, talc in-
duces significant apoptosis in
malignant mesothelioma3 and lung
adenocarcinoma4 cells, but not in
normal pleural mesothelial cells.3
These properties of talc seem
extremely intriguing. Preclinical
studies to determine effects in
asbestos-related nonneoplastic pleural
disease would be interesting, with
the aim of assessing the possible
action of talc in preventing evolution
toward mesothelioma. Appropriate
nonhuman models remain to be
determined.
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POLYUNSATURATED FATTY
ACIDS TO PREVENT
POSTOPERATIVE ATRIAL
FIBRILLATION IN PATIENTS
SUBJECTED TO HEART
SURGERY
To the Editor:
The debate on the effectiveness of
n-3 polyunsaturated fatty acids
(PUFAs) in cardiovascular disease
has recently been fueled by the
publication of 3 meta-analyses.1-3
Furthermore, attempts to apply trial
sequential analysis (TSA) to these
issues have also contributed to the
debate.4,5
With regard to secondary preven-
tion of cardiovascular disease, the
meta-analysis by Kwak and col-
leagues1 found no proof ofThe Journaleffectiveness for PUFAs. Later, a
TSA that was based on the same data
provided a stronger negative conclu-
sion in terms of proof of no effective-
ness (futility).4 Likewise, with regard
to the role of PUFAs to prevent atrial
fibrillation, a meta-analysis showing
no effectiveness was published,2 fol-
lowed by a TSA indicating futility.5
In this framework, the meta-
analysis by Costanzo and associates3
recently published in the Journal has
been focused on the preoperative sup-
plementation of PUFAs to prevent
postoperative atrial fibrillation inof Thoracic and Cardiovascular Surgeheart surgery. The results of this
meta-analysis were borderline,
because most effectiveness indices
were at the limits of statistical
significance.
In an attempt to clarify the uncer-
tainty surrounding the effectiveness
of PUFAs for this indication, we un-
dertook a TSA aimed at reexamining
the same 8 trials evaluated by Cos-
tanzo and associates.3 Our analysis
considered the end point of postopera-
tive atrial fibrillation. Main assump-
tions included 2-sided testing, risk of
type 1 error of 5%, and power ofry c Volume 146, Number 4 991
